Rutgers Cancer Institute | Strategic Alliance Partners

As New Jersey’s only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, Rutgers Cancer Institute offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – these cutting-edge therapies are available to adult and pediatric patients. Some of these treatments are fueled by onsite research in which physicians and scientists work side by side to advance our understanding of cancer and transform laboratory discoveries into clinical practice.

Connect with us:

Latest from Rutgers Cancer Institute


Dr Omene on the Importance of Access to Breast Cancer Screenings in Underserved Populations

May 26, 2023

Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.

Blue Light Cystoscopy Enhances Detection of Cancer in the Bladder

May 11, 2023

Saum Ghodoussipour, MD, shares how some facilities in the tri-state region including Rutgers Cancer Institute and Robert Wood Johnson University Hospital, use enhanced blue light technology with an imaging solution that better highlights cancerous tumors in the bladder.

Addressing the Challenge: Connecting Black Women with Clinical Trials

April 26, 2023

Clinical trials have strikingly low rates of Black participants, even those centered on diseases that disproportionately affect Black women in particular, such as breast cancer, the most commonly diagnosed cancer and the leading cause of cancer death for this population.

$3.2 Million Grant Supports Study of New Genetic Testing Approach to Reduce Racial Health Disparities

April 03, 2023

With a National Cancer Institute grant, investigators from Rutgers Cancer Institute of New Jersey and Georgetown University’s Lombardi Comprehensive Cancer Center will work to close racial disparity gaps in cancer care delivery by examining a novel approach to genetic testing and care based on community identified needs.

Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast Cancer

March 14, 2023

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.